Status:
TERMINATED
Effectiveness and Safety of Combination Mifepristone/Misoprostol for Medical Abortion
Lead Sponsor:
Linepharma International LTD
Conditions:
Medical Abortion
Eligibility:
FEMALE
16-55 years
Brief Summary
National multi-center non interventional study aiming at investigating the effectiveness and safety of the combination mifepristone-misoprostol prescribed in Canada to women for medical termination of...
Detailed Description
Primary Objectives: * Effectiveness of mifepristone-misoprostol for medical abortion at or prior to 63 days gestational age, defined as complete abortion without further intervention within 14 days o...
Eligibility Criteria
Inclusion
- Inclusion criteria
- Women who:
- request elective pregnancy termination in one of the sites participating into the study
- are prescribed mifepristone-misoprostol for this purpose
- provide informed consent to participate in the study.
- Exclusion Criteria:
- Participant who is unable to understand or comply with Health Care Professional instructions or medical abortion regimen
- Participant who is unable or unwilling to provide written informed consent.
Exclusion
Key Trial Info
Start Date :
February 19 2022
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
February 20 2024
Estimated Enrollment :
129 Patients enrolled
Trial Details
Trial ID
NCT04905251
Start Date
February 19 2022
End Date
February 20 2024
Last Update
February 10 2025
Active Locations (6)
Enter a location and click search to find clinical trials sorted by distance.
1
Family Planning Clinic, Moncton City Hospital
Moncton, New Brunswick, Canada, E1C 6Z8
2
Centennial Primary Care
Kentville, Nova Scotia, Canada, B4N 1C2
3
Mud Creek Medical
New Minas, Nova Scotia, Canada, B4N 3R7
4
Manitoulin Health Centre
Mindemoya, Ontario, Canada, P0P 1S0